account_id none on file
legal_name Aptevo Therapeutics Inc.
ticker APVO
cik 1671584
domain aptevotherapeutics.com
linkedin_company_url https://www.linkedin.com/company/aptevo-therapeutics-inc
entry_point_account_id none on file
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 19 executives 11 family 0
why_nownone on file
callsnone on file
filings
This process, which is commonly referred to as “householding,” potentially means extra convenience for stockholders and cost savings for companies.
filing / Aug 31, 2026 / receipt
In calculating the size of the increase in the authorized number of shares issuable under the Fifth Amended Plan, our Board considered, among other things, our hiring plans and expected number of employees, our historical and projected share usage under our stock incentive plans, our “burn rate,” our current overhang in shares issuable upon exercise of outstanding awards granted under our stock incentive plans, the e
filing / Aug 31, 2026 / receipt
In calculating the size of the increase in the authorized number of shares issuable under the Fifth Amended Plan, our Board considered, among other things, our hiring plans and expected number of employees, our historic and projected share usage under our stock incentive plans, our “burn rate,” our current overhang in shares issuable upon exercise of outstanding awards granted under our stock incentive plans or as in
filing / Aug 31, 2026 / receipt
Marvin L. White (Officer & Director)
filing / Aug 31, 2026 / receipt
Jeffrey G. Lamothe (Officer & Director)
filing / Aug 31, 2026 / receipt
Daniel J. Abdun-Nabi (Director)
filing / Aug 31, 2026 / receipt
John E. Niederhuber, M.D. (Director)
filing / Aug 31, 2026 / receipt
Zsolt Harsanyi, Ph.D. (Director)
filing / Aug 31, 2026 / receipt
Grady Grant, III (Director)
filing / Aug 31, 2026 / receipt
Barbara Lopez Kunz (Director)
filing / Aug 31, 2026 / receipt
Seattle office lease, including amendment $ 3,484 $ 3,810 Total operating leases $ 3,484 $ 3,810 10 Lease payments: For the Six Months Ended June 30, (in thousands) 2026 2025 For operating leases $ 688 $ 688 As of June 30, 2026 , the long-term and current portion of the lease liabilities was $ 3.3 million and $ 0.9 million, respectively.
filing / Aug 14, 2026 / receipt
Jeffrey G. Lamothe 61 President and Chief Executive Officer of Aptevo
filing / Jul 31, 2026 / receipt
executives
| Barbara Lopez Kunz | Director nominee | - | receipt |
| Daniel J. Abdun-Nabi | Director | - | receipt |
| Daphne Taylor | SVP & Chief Financial Officer | receipt | |
| Dirk Huebner | Senior Vice President, Chief Medical Officer | - | receipt |
| Grady Grant, III | Director | - | receipt |
| Jeffrey G. Lamothe | President and Chief Executive Officer | - | receipt |
| John E. Niederhuber | Director | - | receipt |
| Marvin L. White | Officer & Director | - | receipt |
| Mary Janatpour | Senior Vice President, Chief Scientific Officer | - | receipt |
| SoYoung Kwon | Senior Vice President, General Counsel, Business Development and Corporate Affairs | - | receipt |
| Zsolt Harsanyi, Ph.D. | Director nominee | - | receipt |
familynone on file
upcoming
| 2026-11-05 | earnings call | scheduled | ir |
changesnone on file
mcp_package_hint
slug aptevo-therapeutics-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$